换一批
换一批Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.
第一作者：
Kirsten,White
第一单位：
Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA 94404, USA kirsten.white@gilead.com.
作者：
主题词
抗逆转录病毒药(Anti-Retroviral Agents);抗逆转录病毒治疗, 高效(Antiretroviral Therapy, Highly Active);临床试验, Ⅲ期(主题)(Clinical Trials, Phase III as Topic);抗药性, 病毒(Drug Resistance, Viral);基因型(Genotype);HIV感染(HIV Infections);HIV-1(HIV-1);人类(Humans);随机对照试验(主题)(Randomized Controlled Trials as Topic);序列分析, DNA(Sequence Analysis, DNA);治疗失败(Treatment Failure)
DOI
10.1093/jac/dkv149
PMID
26108607
发布时间
2022-03-11
- 浏览73
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
